Japan Tissue Engineering Company Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Japan Tissue Engineering Company Limited with three other
companies in this sector in Japan:
Medinet Co., Ltd.
sales of 1.70 billion Japanese Yen [US$16.07 million]
of which 100%
was cell processing),
GNI Group Limited
(2.65 billion Japanese Yen [US$24.97 million]
Trans Genic Inc
(2.30 billion Japanese Yen [US$21.72 million]
of which 50%
was CRO Business).
Japan Tissue Engineering Company Limited reported sales of ¥2.14 billion (US$20.13 million)
March of 2017.
increase of 49.2%
versus 2016, when the company's sales were ¥1.43 billion.
Sales at Japan Tissue Engineering Company Limited have increased during each of the previous five years
(and since 2012, sales have increased a total of 351%).
Sales of Regenerative Medicine Products Business saw an increase
52.8% in 2017, from
¥1.34 billion to ¥2.04 billion.
Not all segments of Japan Tissue Engineering Company Limited experienced an increase in sales in 2017:
sales of Research and Development Support fell 1.4% to ¥91.82 million.